head of the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center's Molecular Pharmacology Program. "Using specially designed peptides, we can build nanomedicines that make ...
head of the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center's Molecular Pharmacology Program. "Using specially designed peptides, we can build nanomedicines that make ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted ...
Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
head of the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center's Molecular Pharmacology Program. "Using specially designed peptides, we can build nanomedicines that make existing ...
18d
AZoLifeSciences on MSNPeptides Boost Anti-Tumor Activity of DrugsA team of scientists has created a ground-breaking method for improving drug formulations by employing specifically engineered peptides.
Research Chemical Sciences has expanded its portfolio to include an array of Advanced Performance Compounds, enhancing the support available for diverse research disciplines. The increased variety ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 ...
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results